The US Food and Drug Administration approved Sarepta’s Exondys 51 (eteplirsen) injection, making it the first drug available for the rare genetic muscle-wasting disease in the country.

SAREPTA, La. -- Working smoke detectors get the credit for a woman surviving a fire in her home Monday night. A woman who lived in a cabin in Sarepta was awakened around 3:40 a.m. to her smoke ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which included a patient death from November in a patient who ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...

Sarepta is currently testing SRP-9001 in the placebo-controlled EMBARK study, which aims to enrol 120 boys with DMD aged four to seven and is due to read out in the latter half of 2023.

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was ...

Sarepta Therapeutics has a 12-month low of $102.15 and a 12-month high of $173.25. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of 87.85 and a beta of 0.75.

CAMBRIDGE, Mass., February 12, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. Solid Biosciences advances ...